Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

NCT05006716 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05006716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05006716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
Lead sponsor
BeOne Medicines
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 13, 2021
Completion date
March 31, 2030
Enrollment
689 (estimated)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell malignancy, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, non-hodgkin lymphoma, richter transformation, small lymphocytic lymphoma, waldenström macroglobulinemia